189 related articles for article (PubMed ID: 8976819)
61. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
62. [Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].
Chatelut E
Bull Cancer; 2011 Nov; 98(11):1253-61. PubMed ID: 22024542
[TBL] [Abstract][Full Text] [Related]
63. A comparative binding of platinum anti-tumour compounds to plasma proteins in the rat (in vivo) and mouse (in vitro).
Perera A; Jackson H; Sharma HL; McAuliffe CA; Fox BW
Chem Biol Interact; 1992 Dec; 85(2-3):199-213. PubMed ID: 1493609
[TBL] [Abstract][Full Text] [Related]
64. Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin.
Borsi JD; Csaki C; Ferencz T; Oster W
Anticancer Drugs; 1996 Jan; 7(1):121-6. PubMed ID: 8742109
[TBL] [Abstract][Full Text] [Related]
65. Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albumin in vivo rats and in vitro study using inductively coupled plasma-mass spectrometory.
Kato R; Sato T; Iwamoto A; Yamazaki T; Nakashiro S; Yoshikai S; Fujimoto A; Imano H; Ijiri Y; Mino Y; Chikuma M; Tanaka K; Hayashi T
Biopharm Drug Dispos; 2019 Jul; 40(7):242-249. PubMed ID: 31219617
[TBL] [Abstract][Full Text] [Related]
66. WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.
Church MW; Blakley BW; Burgio DL; Gupta AK
J Assoc Res Otolaryngol; 2004 Sep; 5(3):227-37. PubMed ID: 15185124
[TBL] [Abstract][Full Text] [Related]
67. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
Capizzi RL; Scheffler BJ; Schein PS
Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
[TBL] [Abstract][Full Text] [Related]
68. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
Capizzi RL
Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
[TBL] [Abstract][Full Text] [Related]
69. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.
Treskes M; Holwerda U; Klein I; Pinedo HM; van der Vijgh WJ
Biochem Pharmacol; 1991 Nov; 42(11):2125-30. PubMed ID: 1659819
[TBL] [Abstract][Full Text] [Related]
70. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve.
Ghazal-Aswad S; Calvert AH; Newell DR
Cancer Chemother Pharmacol; 1996; 37(5):429-34. PubMed ID: 8599865
[TBL] [Abstract][Full Text] [Related]
71. Pharmacokinetics of carboplatin after i.v. administration.
Elferink F; van der Vijgh WJ; Klein I; Vermorken JB; Gall HE; Pinedo HM
Cancer Treat Rep; 1987 Dec; 71(12):1231-7. PubMed ID: 3319135
[TBL] [Abstract][Full Text] [Related]
72. Use of microdialysis to study platinum anticancer agent pharmacokinetics in preclinical models.
Johansen MJ; Thapar N; Newman RA; Madden T
J Exp Ther Oncol; 2002; 2(3):163-73. PubMed ID: 12415633
[TBL] [Abstract][Full Text] [Related]
73. Comparative adverse effect profiles of platinum drugs.
McKeage MJ
Drug Saf; 1995 Oct; 13(4):228-44. PubMed ID: 8573296
[TBL] [Abstract][Full Text] [Related]
74. Pharmacokinetics of amifostine: effects of dose and method of administration.
Shaw LM; Bonner HS; Schuchter L; Schiller J; Lieberman R
Semin Oncol; 1999 Apr; 26(2 Suppl 7):34-6. PubMed ID: 10348258
[TBL] [Abstract][Full Text] [Related]
75. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects.
van der Vijgh WJ; Peters GJ
Semin Oncol; 1994 Oct; 21(5 Suppl 11):2-7. PubMed ID: 7973774
[TBL] [Abstract][Full Text] [Related]
76. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy.
Los G; Verdegaal EM; Mutsaers PH; McVie JG
Cancer Chemother Pharmacol; 1991; 28(3):159-65. PubMed ID: 1855272
[TBL] [Abstract][Full Text] [Related]
77. Comparative distribution and excretion of carboplatin and cisplatin in mice.
Siddik ZH; Jones M; Boxall FE; Harrap KR
Cancer Chemother Pharmacol; 1988; 21(1):19-24. PubMed ID: 3277732
[TBL] [Abstract][Full Text] [Related]
78. A Bayesian dosing method for carboplatin given by continuous infusion for 120 h.
Guillet P; Monjanel S; Nicoara A; Duffaud F; Lacarelle B; Bagarry-Liegey D; Durand A; Catalin J; Favre R
Cancer Chemother Pharmacol; 1997; 40(2):143-9. PubMed ID: 9182836
[TBL] [Abstract][Full Text] [Related]
79. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
[TBL] [Abstract][Full Text] [Related]
80. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action.
Grdina DJ; Shigematsu N; Dale P; Newton GL; Aguilera JA; Fahey RC
Carcinogenesis; 1995 Apr; 16(4):767-74. PubMed ID: 7728953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]